Key Figures of Consolidated Financial Results for 1st Quarter FY2024

1. Financial Summary (IFRS)Q1 FY2024

Q1 FY2023

Variance

August 2nd, 2024
Sumitomo Chemical Co., Ltd.
(Billions of yen)
FY2024(Forecast
FY2023announced in April)

Sales revenue

612.1

563.1

49.0

2,670.0

2,446.9Core operating income (loss)

5.7(53.6)

59.3

100.0

(149.0)Operating income (loss)

11.5(71.7)

83.2

70.0(488.8)Net income (loss) attributable toowners of the parent

24.4(33.2)

57.5

20.0(311.8)

Basic earnings (loss) per share¥ 14.91¥ (20.27)¥ 35.18¥ 12.23¥ (190.69)

Return on equity

2.5%(2.8)%

5.3%

2.1%(29.2)%

Overseas sales revenue

69.2%

65.8%

3.4%

67.8%

68.0%

Exchange rate (yen/$)155.85137.49－145.00144.59Naphtha price (yen/kl)

79,00067,500－75,00069,100*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses
incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments
accounted for using the equity method.

2. Sales Revenue / Core Operating Income by Business Segment (IFRS)(Billions of yen)
FY2024Q1 FY2024

Q1 FY2023

Variance

Sales revenue
Essential Chemicals
Core operating& Plastics
income

201.9

192.4

9.5

900.0

774.0

(20.7)(21.0)

0.3(35.0)(90.7)

Sales revenue
Energy & FunctionalCore operating
Materials
income

68.0

73.4

(5.4)

290.0

300.3

3.7

3.0

0.7

11.0

7.8

Sales revenue

111.5

94.5

17.0

410.0

414.2

Core operating
income

18.5

6.7

11.9

47.0

44.0

Sales revenue

113.3

102.7

10.6

610.0

546.0

Core operating
income

5.0

(7.0)

12.0

62.0

30.9

Sales revenue

97.9

83.0

14.9

370.0

342.7

Core operating
income(0.5)(33.3)

32.7

3.0(133.0)

Sales revenue

19.6

17.3

2.3

90.0

69.8

Core operating
income

2.8

2.4

0.4

8.0

8.1

Sales revenue

－

－

－

－

－

Core operating
income

(3.2)

(4.4)

1.2

4.0

(16.1)

Sales revenue

612.1

563.1

49.0

2,670.0

2,446.9Core operating
income5.7(53.6)

59.3

100.0

(149.0)IT-related
Chemicals
Health & Crop
Sciences

Pharmaceuticals

OthersAdjustments

Total(Forecastannounced in April)

FY2023

3. Summary of Consolidated Statement of Income (IFRS)(Billions of yen)
Variance
Ratio

Q1 FY2024

Q1 FY2023

612.1

563.1

49.0

8.7%

Core operating income (loss)

5.7(53.6)

59.3－

Of which equity in earnings(17.4)(12.0)

(5.3)

－

5.8

(18.1)

24.0

－

10.1

0.7

9.4

－

(3.5)

(19.3)

15.8－

Others

(0.8)

0.4

(1.2)

－

Operating income (loss)

11.5(71.7)

83.2

－

26.0

21.9

4.1

－

29.0

23.8

5.3

－

Income (loss) before taxes

37.5(49.9)

87.3－

Income tax expenses

(3.6)

(1.3)

(2.3)

－

33.9

(51.2)

85.1

－

(9.5)

18.0

(27.5)－

24.4(33.2)

57.5

－

2.5%

(2.8)%

Exchange rate (yen/$)155.85137.49Naphtha price (yen/kl)

79,00067,500Overseas sales revenue ratio

69.2%

65.8%

Sales revenue

Total non-recurring items
Of which gains on sales of property,
plant and equipment, and intangible
assetsOf which restructuring costs

Finance income/expenses
Of which gain on foreign currencytransactions including gain or loss onderivatives

Net income (loss)
Net (income) loss attributable tonon-controlling interests
Net income (loss) attributable toowners of the parent
ROE

Variance

4. Summary of Consolidated Statement of Financial Position (IFRS)(Billions of yen)
30-Jun-24

31-Mar-24

Variance

1,763.5

1,675.9

87.6

234.3

217.4

16.8

604.6

620.0

Inventories

760.9

OthersCurrent Assets
Cash and cash
equivalents
Trade and otherreceivables

Non-current assets
Property, plant andequipment
Goodwill and intangible
assetsOthersTotal

30-Jun-24

31-Mar-24

Variance

2,722.8

2,770.5(47.6)

Trade and other payables

564.3

543.4

21.0

(15.4)

Interest-bearing liabilities

1,518.7

1,563.5(44.8)

709.6

51.3

Others

639.8

663.6

(23.8)

163.8

128.8

35.0

1,226.9

1,164.4

62.6

2,186.2

2,258.9(72.7)

Shareholders' equity

706.4

660.0

46.5

316.5

305.8

10.8

203.9

198.6

5.3

Total

3,949.7

3,934.8

14.9

Ratio of equity attributableto owners of the parent tototal assets

25.9%

24.5%

1.4%

1.2

1.3

(0.1)

Liabilities

Equity

819.9

796.5

23.4

Other components ofequity

561.5

536.7

24.8

Non-controlling interests

804.8

925.7

(120.9)3,949.7

3,934.8

14.9

D/E ratio (times)

5. Summary of Consolidated Statement of Cash Flows (IFRS)(Billions of yen)
Q1 FY2024

Q1 FY2023

Variance

FY2023

Cash flows from operating activities(12.3)(131.9)119.7(51.3)Cash flows from investing activities

82.5(13.4)

95.9(112.2)

Free cash flows

70.2(145.4)215.6(163.6)

Cash flows from financing activities(63.0)

142.0(205.1)

49.2

Others6.9

19.5(12.6)

28.7

Increase (decrease) in cash and cash equivalents

14.1

16.2

(2.1)

(85.6)Cash and cash equivalents at the end of the period

234.3

323.1

(88.9)

217.4

Note: This document has been translated from the Japanese-language original (hereinafter, the "original") for reference purposes
only. In the event of any discrepancy between this translated document and the original, the original shall prevail.
The original of Quarterly Consolidated Financial Statements has undergone a review by the Company's audit firm. Pleaserefer to the Japanese review report for details.

August 2, 2024

Summary of Consolidated Financial Resultsfor First Quarter Fiscal Year 2024
(Under IFRS)
Company name:
Sumitomo Chemical Co., Ltd.
Listing:
Tokyo Stock Exchange
Securities code:
4005
URL:
https://www.sumitomo-chem.co.jp/english/
Representative:
Keiichi Iwata, Representative Director & President
Inquiries:
Shunji Kobayashi, General Manager, Corporate Communications Dept.
Telephone:+81-3-5201-0200
Scheduled date to commence dividend payments:－
Preparation of supplementary material on financial results:
Yes
Holding of financial results briefing:
Yes (for institutional investors and analysts)(All amounts are rounded to the nearest million yen.)

1. Consolidated Financial Results for First Quarter Fiscal Year 2024
(April 1, 2024 to June 30, 2024)(1) Consolidated Operating Results(Percentages indicate year-on-year changes.)Core operating
Sales revenue
incomeOperatingincomeNet income
attributable toowners of theparent

Net income

Total
comprehensive
incomeMillionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%Q1 FY2024

612,144

8.7

5,670

－

11,499－33,886－24,383－69,876(6.2)

Q1 FY2023

563,143(27.3)(53,598)－(71,747)－(51,182)－(33,153)－

74,497(61.3)

Basic earnings Diluted earnings
per shareper shareYen

Yen

Q1 FY2024

14.91

14.90

Q1 FY2023(20.27)－

Reference: Share of profit or loss of investments accounted for using the equity method
Q1 FY2024: ¥(17,352)million
Q1 FY2023:¥(12,042)million
Income before taxes
Q1 FY2024: ¥37,481 million
Q1 FY2023:¥(49,862)million*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses
incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments
accounted for using the equity method.
*For diluted earnings per share for Q1 FY2023, although there are potential shares, they are not listed because they havean anti-dilutive effect.

(2) Consolidated Financial Position
Total assets
As ofTotal equity

Equity attributable toowners of the parent

Ratio of equity attributableto owners of the parent tototal assets

Millions of yen

Millions of yen

Millions of yen%

June 30, 2024

3,949,741

1,226,921

1,022,977

25.9

March 31, 2024

3,934,818

1,164,366

965,753

24.5

2. Dividends
Dividends per share
1st quarterend

2nd quarterend

3rd quarter
end

YearendAnnual

Yen

Yen

Yen

Yen

Yen

FY2023

－

6.00

－

3.00

9.00

FY2024

－
3.00

－

6.00

9.00

FY2024 (Forecast)

Note: Revision of dividend forecasts from the latest announcement: None

3. Consolidated Financial Forecasts for Fiscal Year 2024
(April 1, 2024 to March 31, 2025)(Percentages indicate year-on-year changes.)
Net income
Basic earnings
attributable to owners
per shareof the parent

Sales revenue

Core operating
incomeOperatingincomeMillionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%YenFirst-half of FY2024

－

－

－

－

－

－

－

－

－

Full-year of FY2024

2,670,000

9.1

100,000－

70,000－20,000－12.23

Note: Revision of financial forecasts from the latest announcement: None
*The consolidated financial forecast for the first-half of FY2024 is not disclosed due to difficulties with predicting.

Notes:(1) Significant changes in the scope of consolidation during the period: None
Newly included:－
Excluded:－(2) Changes in accounting policies and changes in accounting estimates(i)
Changes in accounting policies required by IFRS: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None
(3) Number of shares issued (common shares)(i)
Total number of shares issued at the end of the period (including treasury shares)(ii)

As of June 30, 2024

1,656,449,145 shares

As of March 31, 2024

1,656,449,145 shares

Number of treasury shares at the end of the period
As of June 30, 2024
As of March 31, 2024

(iii)

20,504,544 shares
20,500,922 shares

Average number of shares outstanding during the period
Three Months ended June 30, 2024
Three Months ended June 30, 2023

1,635,748,188 shares
1,635,216,496 shares* Review of the Japanese-language original of the attached quarterly consolidated financial statements by certified public
accountants or an audit firm: Yes (voluntary)* Notes to appropriate use of forecasts and other special items:
Descriptions regarding forward-looking statements about the future performance of the Company contained in thissummary are based on information currently available to the Company and certain assumptions judged reasonable andinvolve risks and uncertainties. The important factors that could cause actual results to differ materially from those
discussed in the forward-looking statements include, but are not limited to, general economic conditions in the
Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; risein prices of raw materials; and fluctuations in foreign exchange rates.

Attachments
1. Summary of Operating Results for First Quarter Fiscal Year 2024 ....................................................2(1) Operating Results ...........................................................................................................................2(2) Consolidated Financial Position ......................................................................................................3(3) Consolidated Forecast and Other Forward-Looking Information ....................................................3
2. Consolidated Financial Statements and Major Notes ..........................................................................4(1) Consolidated Statement of Financial Position ................................................................................4(2) Consolidated Statement of Income andConsolidated Statement of Comprehensive Income .......................................................................6(3) Consolidated Statement of Changes in Equity ...............................................................................8(4) Consolidated Statement of Cash Flows ......................................................................................... 10(5) Notes to Consolidated Financial Statements..................................................................................

11(Framework of Financial Report) .................................................................................................. 11(Going Concern Assumption) ........................................................................................................ 11(Segment Information) .................................................................................................................. 11

1

1. Summary of Operating Results for First Quarter Fiscal Year 2024
(1) Operating Results
For Q1 FY2024, the Group's sales revenue increased by ¥49.0 billion compared to Q1 FY2023, to ¥612.1 billion. In
terms of profits and losses, core operating income* was ¥5.7 billion, operating income was ¥11.5 billion, and net income
attributable to owners of the parent was ¥24.4 billion. Results in every category of income improved compared to Q1
FY2023.
*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses
incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments
accounted for using the equity method.
The financial results by business segment for Q1 FY2024 are as follows:
Essential Chemicals & Plastics
Selling prices for synthetic resins, methyl methacrylate and various industrial chemicals increased due to higher raw
material prices. As a result, sales revenue increased by ¥9.5 billion from Q1 FY2023, to ¥201.9 billion. There was adeterioration in the financial performance of Rabigh Refining and Petrochemical Company, an affiliated company
accounted for by the equity-method, but because of an improvement in market conditions, core operating income was
essentially unchanged from Q1 FY2023, with a loss of ¥20.7 billion.
Energy & Functional Materials
Market conditions for battery metals for cathode materials remained at a low level. In addition, shipments of aluminum
declined. On the other hand, shipments of products for automotive-related applications, which had been weak in Q1
FY2023, increased. As a result, sales revenue decreased by ¥5.4 billion from Q1 FY2023, to ¥68.0 billion. Core
operating income was ¥3.7 billion, increased by ¥0.7 billion from Q1 FY2023 because of lower fixed costs and otherfactors.
IT-related Chemicals
Shipments of display-related materials and processing materials for semiconductors, such as high-purity chemicals andphotoresists, increased because of higher demand. As a result, sales revenue increased by ¥17.0 billion from Q1
FY2023, to ¥111.5 billion. Core operating income was ¥18.5 billion, increased by ¥11.9 billion from Q1 FY2023.
Health & Crop Sciences
Shipments of crop protection products in such locations as North America and India increased. Moreover, market
conditions for methionine (feed additives) improved compared to Q1 FY2023. As a result, sales revenue increased by¥10.6 billion from Q1 FY2023 to ¥113.3 billion. Core operating income was ¥5.0 billion, increased by ¥12.0 billion fromQ1 FY2023.
Pharmaceuticals
In North America, there was an increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer),
MYFEMBREE® (therapeutic agent for uterine fibroids and endometriosis) and GEMTESA® (therapeutic agent for
overactive bladder). On the other hand, in Japan, sales revenues were affected by National Health Insurance (NHI) drug
price revisions. As a result, sales revenue increased by ¥14.9 billion from Q1 FY2023, to ¥97.9 billion. Core operating
income posted a loss of ¥0.5 billion, improved by ¥32.7 billion from Q1 FY2023, because of increased sales revenue andsignificant reduction in selling, general and administrative expenses, including a decline in research and development
expenses. These reductions resulted from the manifestation of effects of business structure improvement through therestructuring of the Group companies in North America and the selection and concentration of research and development
investments.

2

Others
In addition to the above five segments, the Group supplies electric power and steam, designs chemical plants andsupervises the construction of those facilities, provides transportation and warehousing, and conducts physical property
analysis and environmental analysis. Sales revenue of these businesses increased by ¥2.3 billion from Q1 FY2023, to¥19.6 billion, and core operating income increased by ¥0.4 billion from Q1 FY2023, to ¥2.8 billion.

(2) Consolidated Financial Position
As of the end of Q1 FY2024, total assets increased by ¥14.9 billion compared to the end of FY2023, to ¥3,949.7 billion
due to the effect of foreign exchange conversions from the weak yen. Mainly inventories increased.
Total liabilities decreased by ¥47.6 billion compared to the end of FY2023, to ¥2,722.8 billion. Interest-bearing liabilities
decreased by ¥44.8 billion compared to the end of FY2023, to ¥1,518.7 billion.
Total equity (including non-controlling interests) increased by ¥62.6 billion compared to the end of FY2023, to ¥1,226.9
billion, owing to net income and the increase of exchange differences on conversion of foreign operations resulting fromthe weak yen. The ratio of equity attributable to the owners of the parent company increased by 1.4 percentage points
compared to the end of FY2023, to 25.9%.

(3) Consolidated Forecast and Other Forward-Looking Information
There is no change from the consolidated financial forecasts announced on April 30, 2024.

3

2. Consolidated Financial Statements and Major Notes(1) Consolidated Statement of Financial Position
Millions of yen

As of June 30, 2024

As of March 31, 2024

AssetsCurrent assets:
Cash and cash equivalents¥

Trade and other receivables

234,258¥

604,600

217,449
620,022

Other financial assets

55,231

31,338Inventories

760,915

709,637

Other current assets

93,16379,077

1,748,167

1,657,523

15,36318,3591,763,530

1,675,882

819,942796,526

Subtotal
Assets held for sale
Total current assets
Non-current assets:
Property, plant and equipment
Goodwill

278,547

263,757

Intangible assets

282,905

272,921

Investments accounted for using the equity method

317,363

319,988

Other financial assets

298,795

412,747

Retirement benefit assets

110,436

110,390

Deferred tax assets

42,211

37,070

Other non-current assets

36,01245,5372,186,211

2,258,936

Total non-current assets
Total assets¥

4

3,949,741¥

3,934,818

Millions of yen

As of June 30, 2024

As of March 31, 2024

Liabilities and equity
Liabilities
Current liabilities:
Bonds and borrowings¥

566,734¥

585,905

Trade and other payables

564,337

543,384

Other financial liabilities

78,967

77,610

Income taxes payable

29,207

8,545

Provisions

98,11890,919Other current liabilities

105,007

129,087

1,442,370

1,435,450

18,2258,037

1,460,595

1,443,487

Bonds and borrowings

951,999

977,581Subtotal
Liabilities directly associated with assets held for sale
Total current liabilities
Non-current liabilities:
Other financial liabilities

100,562

100,144

Retirement benefit liabilities

30,83230,589Provisions

32,38446,059Deferred tax liabilities

100,480

121,146

Other non-current liabilities

45,96851,446

1,262,225

1,326,965

2,722,820

2,770,452

Share capital

89,93889,938

Capital surplus

213

237

Retained earnings

624,651

578,175

Treasury shares(8,356)(8,355)

316,649

304,033

(118)

1,725

Total non-current liabilities
Total liabilities
EquityOther components of equity
Other comprehensive income associated withassets held for sale
Equity attributable to owners of the parent
Non-controlling interests
Total equity
Total liabilities and equity¥

5

1,022,977

965,753

203,944

198,6131,226,921

1,164,366

3,949,741¥

3,934,818

(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income
Consolidated Statement of Income
First quarter ended June 30, 2024 and 2023
Millions of yen

Q1 FY2024

Sales revenue¥

Cost of sales
Gross profit
Selling, general and administrative expenses
Other operating income
Other operating expenses
Share of profit (loss) of investments accounted forusing the equity method
Operating income (loss)

612,144Q1 FY2023¥

563,143(440,306)(434,011)

171,838

129,132(151,235)(178,072)

13,632

10,135(5,384)(20,900)(17,352)(12,042)

11,499(71,747)

Finance income

40,162

39,171

Finance expenses(14,180)(17,286)

Income (loss) before taxes

37,481(49,862)

Income tax expenses(3,595)(1,320)33,886(51,182)

Net income (loss)
Net income (loss) attributable to:
Owners of the parent

24,383(33,153)

Non-controlling interests

9,503(18,029)

Net income (loss)¥

Yen

33,886Q1 FY2024¥(51,182)

Q1 FY2023

Earnings per share:
Basic earnings (loss) per share

14.91(20.27)

Diluted earnings per share

14.90

－

6

Consolidated Statement of Comprehensive Income
First quarter ended June 30, 2024 and 2023
Millions of yen

Q1 FY2024

Net income (loss)¥

Q1 FY2023

33,886¥(51,182)

Other comprehensive income:Items that will not be reclassified to profit or loss
Remeasurements of financial assets measured at fair value
through other comprehensive income
Remeasurements of defined benefit plans
Share of other comprehensive income of investments
accounted for using the equity method
Total items that will not be reclassified to profit or loss

(5,376)

36,468

(7)

(5)

981

407

(4,402)36,870387

816

29,117

81,672

10,8886,321

40,39288,80935,990125,679

69,87674,497

Owners of the parent

62,15763,422

Non-controlling interests

7,719

11,075

Items that may be subsequently reclassified to profit or loss
Cash flow hedge
Exchange differences on conversion of foreign operations
Share of other comprehensive income of investments
accounted for using the equity method
Total items that may be subsequently reclassified to
profit or loss
Other comprehensive income, net of taxes
Total comprehensive income

Total comprehensive income attributable to:Total comprehensive income¥

769,876¥74,497

(3) Consolidated Statement of Changes in Equity
First quarter ended June 30, 2024
Equity attributable to owners of the parent
Other components of equity
Share
capitalMillions of yen
Balance as of April 1, 2024¥

Capitalsurplus¥237¥ 578,175－－

24,383－－－

Other comprehensive income

－

－

－

－

(623)

274

－

－

24,383

－

(623)

274

Purchase of treasury shares

－

－

－

(1)

－

－

Disposal of treasury shares

－

(0)

－

0

－

－

Dividends
Changes resulting from loss ofcontrol of subsidiaries
Change in interest due totransactions with
non-controlling interests
Transfer from other componentsof equity to retained earnings
Transfer to other comprehensive
income associated with assets
held for sale
Total transactions with owners－－(4,908)

－

－

－

－

－

－

－

－

－

－

(24)

－

－

－

－

－

－

27,001－(26,727)

(274)

－

－

－

－

－

－

(1)

(26,727)(8,356) ¥56,098

Balance as of June 30, 2024¥

Treasuryshares

Net income (loss)
Total comprehensive income

89,938Retainedearnings

Remeasurementsof financial
assets measured Remeasurements
at fair valueof defined benefit
through otherplans
comprehensive
income－¥89,938¥(24)

22,093213¥ 624,651¥(8,355) ¥83,448

¥

－

(274)
¥

－

Equity attributable to owners of the parent
Other components of equity

Balance as of April 1, 2024

Cash flow
hedgesExchangedifferences on
conversion offoreign
operations

Total

¥

Other
comprehensive
incomeassociated withassets held forsale

Equityattributableto owners of
the parent

Noncontrollinginterests

Total equity¥¥ 1,164,366

319¥ 220,266¥ 304,033

1,725¥ 965,753¥ 198,613

Net income (loss)

－

－

－

－

24,383

9,503

33,886

Other comprehensive income

387

39,46139,499(1,725)37,774(1,784)35,990Total comprehensive income

387

39,46139,499(1,725)62,157

7,719

69,876

Purchase of treasury shares

－

－

－

－

(1)

－

(1)

Disposal of treasury shares

－

－

－

－

0

－

0

Dividends
Changes resulting from loss ofcontrol of subsidiaries
Change in interest due totransactions with
non-controlling interests
Transfer from other componentsof equity to retained earnings
Transfer to other comprehensive
income associated with assets
held for sale
Total transactions with owners

－

－

－

－

(4,908)(2,440)(7,348)

－

－

－

－

－

28

28

－

－

－

－

(24)

24

－

－

－

(27,001)

－

－

－

－

－

118

118

(118)

－

－

－

－

118

(26,883)(118)(4,933)(2,388)(7,321)706¥ 259,845¥ 316,649(118) ¥1,022,977¥ 203,944¥ 1,226,921

Balance as of June 30, 2024

¥

8

¥

First quarter ended June 30, 2023
Equity attributable to owners of the parent
Other components of equity
Share
capitalMillions of yen
Balance as of April 1, 2023¥

Capitalsurplus¥Treasuryshares¥－¥ 891,552

Net income (loss)－－(33,153)－－－

Other comprehensive income

－

－

－

－

21,714

10

Total comprehensive income

89,810Retainedearnings

Remeasurementsof financial
assets measured Remeasurements
at fair valueof defined benefit
through otherplans
comprehensive
income(8,349) ¥81,869¥－－－(33,153)－

21,71410

Purchase of treasury shares

－

－

－

(1)

－

－

Disposal of treasury shares

－

0

－

0

－

－

Dividends
Changes resulting from loss ofcontrol of subsidiaries
Change in interest due totransactions with
non-controlling interests
Transfer from other componentsof equity to retained earnings
Transfer to other comprehensive
income associated with assets
held for sale
Total transactions with owners－－(9,812)

－

－

－

－

－

349

－

－

－

－

－

－

－

－

－

－

－

5,366

－

(5,356)

(10)

－

－

－

－

－

－

－

0

(4,097)(1)(5,356)(10)0¥ 854,302(8,350) ¥98,227

Balance as of June 30, 2023¥

89,810¥¥¥－Equity attributable to owners of the parent
Other components of equity
Cash flow
hedgesBalance as of April 1, 2023¥

Exchangedifferences on
conversion offoreign
operations(539) ¥ 116,500

Total¥ 197,830

Othercomprehensive
incomeassociated withassets held forsale

Equityattributableto owners of
the parent

Noncontrollinginterests

Total equity¥349¥1,171,192¥ 317,997¥ 1,489,189

Net income (loss)

－

－

－

－

(33,153)(18,029)(51,182)

Other comprehensive income

869

73,982

96,575－96,575

29,104

125,679869

73,982

96,575－63,422

11,07574,497Purchase of treasury shares

－

－

－

－

(1)

－

(1)

Disposal of treasury shares

－

－

－

－

0

－

0

Dividends
Changes resulting from loss ofcontrol of subsidiaries
Change in interest due totransactions with
non-controlling interests
Transfer from other componentsof equity to retained earnings
Transfer to other comprehensive
income associated with assets
held for sale
Total transactions with owners

－

－

－

－

(9,812)(3,934)(13,746)

－

－

－

(349)

－

－

－

－

－

－

－

－

－

－

－

－

(5,366)

－

－

－

－

－

－

－

－

－

－

－

Total comprehensive income

Balance as of June 30, 2023

¥

－

－

(5,366)330¥ 190,482¥ 289,039

9

¥

(349)

(9,813)(3,934)(13,747)－¥1,224,801¥ 325,138¥ 1,549,939

(4) Consolidated Statement of Cash FlowsFirst quarter ended June 30, 2024 and 2023
Millions of yen
Cash flows from operating activities:
Income (loss) before taxes
Depreciation and amortization
Share of (profit) loss of investments accounted for using the equity method
Interest and dividend income
Interest expenses
Restructuring costs(Gain) loss on sale of property, plant and equipment, and intangible assets(Increase) decrease in trade receivables(Increase) decrease in inventories
Increase (decrease) in trade payables
Increase (decrease) in unearned revenue
Increase (decrease) in provisions
Others, net
SubtotalInterest and dividends received
Interest paid
Income taxes paid
Restructuring costs paid
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Net (increase) decrease in securities
Purchase of property, plant and equipment, and intangible assets
Proceeds from sales of property, plant and equipment, and intangible assets
Proceeds from sales of subsidiaries
Payments for sales of subsidiaries
Purchase of other financial assets
Proceeds from sales and redemption of other financial assets
Others, net
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Net increase (decrease) in short-term borrowings
Net increase (decrease) in commercial paper
Proceeds from long-term borrowings
Repayments of long-term borrowings
Redemption of bonds
Repayments of finance lease liabilities
Cash dividends paid
Cash dividends paid to non-controlling interests
Others, net
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Net increase (decrease) in cash and cash equivalents
resulting from transfer to assets held for sale
Cash and cash equivalents at the end of the period

10

Q1 FY2024

Q1 FY2023¥¥¥

37,481
33,56917,352(6,589)7,425
3,533(10,135)
35,473(39,931)
3,782(2,961)
1,268(76,316)
3,951
10,643(7,808)(8,104)(10,940)(12,258)(49,862)
39,30012,042(5,581)
6,784
19,297(725)
53,451(34,127)(22,303)(2,927)(35,791)(82,192)(102,634)
9,034(6,875)(30,749)(694)(131,918)(3,454)(36,076)
12,242－(3,911)(902)
113,633
962
82,494(4,599)(44,188)430
11,074－(2,343)24,788
1,399(13,439)(21,922)18,00034(36,718)(10,000)(4,550)(4,919)(2,441)(524)(63,040)
6,862
14,058217,449

79,40653,00029,956(1,815)－(4,340)(9,821)(3,888)(450)
142,048
19,464
16,155
305,844

2,751

1,135

234,258¥

323,134

(5) Notes to Consolidated Financial Statements
Framework of Financial Report
The Group's quarterly consolidated financial statements are prepared in accordance with Article 5, Paragraph 2 of theTokyo Stock Exchange, Inc.'s Standards for the Preparation of Quarterly Financial Statements, applying the omitted
disclosures as set forth in Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements.

Going Concern Assumption
Not applicable.

Segment Information
1. Reportable Segments
The reportable segments of the Group refer to business units for which separate financial information is available andthat are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management
resources and evaluate the business performance of each business unit.
The Group divides its operations into business sectors identified by products and services, which manage
manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing
comprehensive domestic and overseas strategies with respect to its products and services, and operates its businessactivities.
Accordingly, the Group has five reportable segments based on its products and services in accordance with its businesssectors, including "Essential Chemicals & Plastics," "Energy & Functional Materials," "IT-related Chemicals," "Health &Crop Sciences," and "Pharmaceuticals."
The major products and services of each reportable segment are as follows:

Reportable Segment

Major Products and Services

Essential Chemicals &Plastics

Synthetic resins, raw materials for synthetic fibers, various industrial chemicals,
methyl methacrylate products, synthetic resin processed products, etc.

Energy & Functional
Materials

Alumina, aluminum, specialty chemicals, additives, synthetic rubber, engineering
plastics, battery materials, etc.

IT-related Chemicals

Optical products, semiconductor processing materials, compound semiconductormaterials, touch screen sensor panels, etc.

Health & Crop Sciences

Crop protection chemicals, fertilizers, agricultural materials, household insecticides,
products for control of infectious diseases, feed additives, active pharmaceuticalingredients and intermediates, etc.

Pharmaceuticals

Pharmaceuticals for medical treatment, radiopharmaceuticals, etc.

2. Reportable Segment Information
The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated
financial statements. The segment profit or loss is core operating income, which is calculated from operating income
after excluding effects from non-recurring factors.
Inter-segment sales revenue is based on market prices.

11

First Quarter Fiscal Year 2024

Millions of yen

Essential
Chemicals &Plastics

Energy &Functional
Materials

IT-related
Chemicals

Health &Crop
Sciences

Pharmaceuticals

Total

Others(Note 1)

Adjustments(Note 2)

Consolidated

Sales revenue:
Sales revenues fromexternal customers¥

201,893 ¥

67,989 ¥111,471 ¥

113,314 ¥

97,917 ¥592,584 ¥

19,560 ¥

1,509

4,214

118

361

1

6,203

18,714(24,917)－

Total sales revenue

203,40272,203

111,589

113,675

97,918598,787

38,274(24,917)612,144

Segment profit (loss)¥: core operating income (loss)(20,701) ¥3,745 ¥

18,549 ¥2,832 ¥

(3,176) ¥Inter-segment sales
revenues

4,962 ¥

(541) ¥

6,014 ¥

－ ¥612,144

5,670

Note 1: "Others" represents businesses such as supplying electrical power and steam, providing services for the design, engineering, andconstruction management of chemical plants, providing transport and warehousing, and conducting materials and environmental
analysis, which are not included in reportable segments.
Note 2: ¥(3,176) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥329 million and corporate
expenses of ¥(3,505) million unallocated to each reportable segment. Corporate expenses are mainly research and development
expenses for company-wide research, which are not attributed to reportable segments.

First Quarter Fiscal Year 2023

Millions of yen

Essential
Chemicals &Plastics

Energy &Functional
Materials

IT-related
Chemicals

Health &Crop
Sciences

Pharmaceuticals

Total

Others(Note 1)

Adjustments(Note 2)

Consolidated

Sales revenue:
Sales revenues fromexternal customers¥

192,353 ¥

73,383 ¥94,451 ¥102,707 ¥82,985 ¥545,879 ¥17,264 ¥

1,361

5,466

110

762

1

7,700

20,164(27,864)－

Total sales revenue

193,71478,84994,561

103,469

82,986

553,579

37,428(27,864)

563,143

Segment profit (loss)¥: core operating income (loss)(21,005) ¥3,004 ¥

6,669 ¥

(33,273) ¥(51,654) ¥2,430 ¥

(4,374) ¥(53,598)

Inter-segment sales
revenues(7,049) ¥－ ¥563,143

Note 1: "Others" represents businesses such as supplying electrical power and steam, providing services for the design, engineering, andconstruction management of chemical plants, providing transport and warehousing, and conducting materials and environmental
analysis, which are not included in reportable segments.
Note 2: ¥(4,374) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥5 million and corporate expensesof ¥(4,379) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses
for company-wide research, which are not attributed to reportable segments.

12Adjustments to income (loss) before taxes from core operating income (loss) were as follows:

Millions of yen

Q1 FY2024

Core operating income (loss)¥

Q1 FY2023

5,670

¥

(53,598)

Gains on sales of property, plant and equipment, and intangible assets

10,135725

Restructuring costs(3,533)(19,297)

Changes in fair value of contingent consideration

(78)

(38)

Others, net

(695)

461

Operating income (loss)

11,499(71,747)

Finance income

40,162

39,171

Finance expenses(14,180)(17,286)

Income (loss) before taxes¥

13

37,481¥(49,862)